Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>Relationship between plasma SDX-7320 Cmax or AUC and change in platelets</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Monica M. Mita (21585118) (author)
Άλλοι συγγραφείς:	Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
Έκδοση:	2025
Θέματα:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Protein biomarkers Pharmacology Pharmacokinetics and pharmacodynamics Phase I Clinical Trials
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια